Loxo Oncology CS (LOXO)
$234.80 0.00 (0.00%)
8:51 EST LOXO Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 7.06B
PE Ratio -52.53
Volume (Avg. Vol.)
Day's Range 234.80 - 234.80
52-Week Range -
Dividend & Yield N/A (N/A)
LOXO Stock Predictions, Articles, and Loxo Oncology CS News
- From InvestorPlace
- From the Web
Eli Lilly offers a massive premium, paying $8 billion to buy Loxo Oncology. What's in it for Lilly and its shareholders?
Loxo Oncology (LOXO) stock was flying high on Monday following news of an $8-billion deal between it and Eli Lilly (LLY).
On a year-to-date basis, SBIO still looks good, up 14.30%, or 310 basis points better than the Nasdaq Biotechnology Index. Year-to-date, SBIO is also outpacing the equal-weight S&P Biotechnology Select Industry Index.
These seven top stocks all boast substantial support from the Street. But that's not all ... they also have massive upside potential for the next few months, making these stocks a perfect choice to boost your 2018 portfolio performance.
U.S. equities moved lower on Monday amid a terror attack in London and several other concerns muddying up the geopolitical picture.
Loxo Oncology (LOXO) shares were in orbit on Monday following three incredibly successful cancer drug trials for Larotrectinib.